New Delhi, Feb. 15 -- Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a significant increase in topline by 35.14%, with profit reaching Rs.347.96 Cr. This marks a remarkable turnaround from the loss of Rs.351.37 Cr reported during the same period in the previous fiscal year.

Despite the impressive year-over-year growth, the company experienced a slight decline of 1.35% in revenue compared to the previous quarter. Additionally, the Selling, General & Administrative expenses rose by 0.25% quarter-on-quarter and increased by 4.71% year-on-year.

The operating income saw a decrease of 0.86% compared to the previous quarter but displayed a substantial increase of 210.42% y...